Melbourne, Australia & Tarrytown, New York | April 13, 2026
Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to co-develop and commercialize next-generation radiopharmaceutical therapies for oncology, combining Telix’s radiopharmaceutical development and manufacturing capabilities with Regeneron’s antibody discovery and biologics expertise. The agreement includes an upfront payment of $40 million, with the potential for up to $2.1 billion in milestone payments and royalties, highlighting the significant commercial and clinical potential of this partnership. The collaboration aims to accelerate the development of precision-targeted cancer therapies, particularly for hard-to-treat solid tumors, representing a major step forward in the evolution of radiopharma-based precision oncology
Strategic Collaboration Combines Complementary Technologies
The partnership leverages Telix’s strength in radiopharmaceutical innovation, global manufacturing infrastructure, and supply chain capabilities, alongside Regeneron’s advanced antibody engineering platforms, including its proprietary VelocImmune® technology. By integrating these capabilities, the companies aim to develop targeted radiopharmaceutical therapies that deliver radioactive payloads directly to tumor cells, enhancing therapeutic precision while minimizing systemic toxicity.
The collaboration will initially focus on multiple solid tumor targets, utilizing antibodies derived from Regeneron’s portfolio to create highly specific and effective treatment modalities. This approach underscores a growing industry shift toward combination technologies that merge biologics with radiotherapy for improved cancer outcomes.
Precision Oncology and Diagnostic Integration Drive Innovation
Advertisement
A key component of the collaboration is the joint development of radio-diagnostic tools, which will support patient selection, treatment monitoring, and response assessment. This integration of diagnostics with therapeutics reflects the principles of precision medicine, enabling clinicians to tailor treatments based on individual patient profiles and tumor characteristics.
Radiopharmaceutical therapies are increasingly recognized as a next-generation modality in oncology, offering the ability to target cancer cells with high specificity while providing real-time insights into treatment effectiveness. By combining therapeutic and diagnostic capabilities, Telix and Regeneron aim to create a comprehensive oncology platform that enhances both clinical decision-making and patient outcomes
Flexible Commercial Model and Global Development Strategy
The agreement establishes a 50/50 cost and profit-sharing model, allowing both companies to equally participate in the development and commercialization of the therapies. Telix retains the option to co-fund and co-promote products, while also having the flexibility to receive milestone payments and royalties if it opts out of certain programs. This structure supports a scalable and adaptable collaboration framework, enabling the partners to expand into additional programs over time.
The collaboration also emphasizes global development and commercialization, leveraging Telix’s manufacturing capabilities and Regeneron’s extensive clinical and regulatory experience to accelerate the delivery of innovative therapies to patients worldwide.
Advancing the Future of Radiopharmaceutical Oncology
Radiopharmaceutical therapies represent a rapidly emerging frontier in cancer treatment, combining targeted biologics with radioactive isotopes to deliver potent anti-tumor effects. This collaboration positions both companies at the forefront of this field, with the potential to address significant unmet medical needs in oncology, including lung cancer and other aggressive malignancies. By harnessing cutting-edge technologies and a shared commitment to innovation, Telix and Regeneron aim to expand the boundaries of cancer therapy and provide new treatment options for patients with limited alternatives.
The strategic collaboration between Telix and Regeneron marks a significant milestone in the advancement of radiopharmaceutical and precision oncology technologies. With strong financial backing, complementary expertise, and a shared vision for innovation, the partnership is well-positioned to deliver next-generation cancer therapies that combine efficacy, precision, and scalability. As development progresses, this collaboration could play a pivotal role in shaping the future of targeted oncology treatments and integrated diagnostic solutions.
Source: Telix Regeneron press release
